SEARCH

SEARCH BY CITATION

References

  • 1
    Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996; 85: 30710.
  • 2
    Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 1997; 61: 186178.
  • 3
    Seki N, Sudo Y, Yoshioka T et al. Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity. J Immunol 1988; 140: 147784.
  • 4
    Taylor PC, Plater-Zyberk C, Maini RN. The role of the B cells in the adoptive transfer of collagen-induced arthritis from DBA/1 (H-2q) to SCID (H-2d) mice. Eur J Immunol 1995; 25: 7639.
  • 5
    Holmdahl R, Jansson L, Larsson A, Jonsson R. Arthritis in DBA/1 mice induced with passively transferred type II collagen immune serum. Immunohistopathology and serum levels of anti-type II collagen auto-antibodies. Scand J Immunol 1990; 31: 14757.
  • 6
    Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40: 20511.
  • 7
    Ranges GE, Sriram S, Cooper SM. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 1985; 162: 110510.
  • 8
    Banerjee S, Wei BY, Hillman K, Luthra HS, David CS. Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor antibody. J Immunol 1988; 141: 11504.
  • 9
    Chiocchia G, Boissier MC, Fournier C. Therapy against murine collagen-induced arthritis with T cell receptor V beta-specific antibodies. Eur J Immunol 1991; 21: 2899905.
  • 10
    Moder KG, Luthra HS, Kubo R, Griffiths M, David CS. Prevention of collagen induced arthritis in mice by treatment with an antibody directed against the T cell receptor alpha beta framework. Autoimmunity 1992; 11: 21924.
  • 11
    Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993; 261: 132830.
  • 12
    Webb LM, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 1996; 26: 23208.
  • 13
    Yoshioka T, Nakajima A, Akiba H, Ishiwata T, Asano G, Yoshino S, Yagita H, Okumura K. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol 2000; 30: 281523.
  • 14
    Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT, Kwon BS. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993; 150: 77181.
  • 15
    Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3: 6825.
  • 16
    Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998; 190: 16772.
  • 17
    Wilcox RA, Chapoval AI, Gorski KS et al. Cutting edge: expression of functional CD137 receptor by dendritic cells. J Immunol 2002; 168: 42627.
  • 18
    Futagawa T, Akiba H, Kodama T, Takeda K, Hosada Y, Yagita H, Okumura K. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 2002; 14: 27586.
  • 19
    Alderson MR, Smith CA, Tough TW et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol 1994; 24: 221927.
  • 20
    Pollok KE, Kim YJ, Hurtado J, Zhou Z, Kim KK, Kwon BS. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells. Eur J Immunol 1994; 24: 36774.
  • 21
    Hurtado JC, Kim YJ, Kwon BS. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol 1997; 158: 26009.
  • 22
    Shuford WW, Klussman K, Tritchler DD et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997; 186: 4755.
  • 23
    Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999; 162: 503740.
  • 24
    Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 1998; 28: 111621.
  • 25
    Mittler RS, Bailey TS, Klussman K, Trailsmith MD, Hoffmann MK. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med 1999; 190: 153540.
  • 26
    Foell J, Strahotin S, O'Neil SP et al. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB×NZW F1 mice. J Clin Invest 2003; 111: 150518.
  • 27
    Sun Y, Chen HM, Subudhi SK, Chen J, Koka R, Chen L, Fu YX. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 2002; 8: 14051413.
  • 28
    Holmdahl R, Klareskog L, Rubin K, Larsson E, Wigzell H. T lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones. Scand J Immunol 1985; 22: 295306.
  • 29
    Stuart JM, Dixon FJ. Serum transfer of collagen-induced arthritis in mice. J Exp Med 1983; 158: 37892.
  • 30
    Kadowaki KM, Matsuno H, Tsuji H, Tunru I. CD4+ T cells from collagen-induced arthritic mice are essential to transfer arthritis into severe combined immunodeficient mice. Clin Exp Immunol 1994; 97: 2128.
  • 31
    Kyburz D, Carson DA, Corr M. The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/B×N mouse model of rheumatoid arthritis. Arthritis Rheum 2000; 43: 25717.
  • 32
    Wang H, Marsters SA, Baker T et al. TACI–ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001; 2: 6327.
  • 33
    Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegard D, Van Den Berg WB. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res 1999; 1: 8191.
  • 34
    Joosten LA, Helsen MM, Saxne T, Van De Loo FA, Heinegard D, Van Den Berg WB. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999; 163: 504955.
  • 35
    Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002; 195: 695704.
  • 36
    Cosmi L, Liotta F, Lazzeri E et al. Human CD28+ CD25+ thymocytes sharing phenotypic and functional features with CD4+ CD25+ regulatory thymocytes. Blood 2003; 102: 4107414.
  • 37
    Ciubotariu R, Colovai AI, Pennesi G, Liu Z, Smith D, Berlocco P, Cortesini R, Suciu-Foca N. Specific suppression of human CD4+ Th cell responses to pig MHC antigens by CD8+ CD28- regulatory T cells. J Immunol 1998; 161: 5193202.
  • 38
    Liu Z, Tugulea S, Cortesini R, Suciu-Foca N. Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+ CD28- T cells. Int Immunol 1998; 10: 77583.
  • 39
    Jiang S, Tugulea S, Pennesi G et al. Induction of MHC-class I restricted human suppressor T cells by peptide priming in vitro. Hum Immunol 1998; 59: 6909.
  • 40
    Li J, Liu Z, Jiang S, Cortesini R, Lederman S, Suciu-Foca N. T suppressor lymphocytes inhibit NF-kappa B-mediated transcription of CD86 gene in APC. J Immunol 1999; 163: 638692.
  • 41
    Colovai AI, Liu Z, Ciubotariu R, Lederman S, Cortesini R, Suciu-Foca N. Induction of xenoreactive CD4+ T-cell anergy by suppressor CD8+ CD28- T cells. Transplantation 2000; 69: 130410.
  • 42
    Najafian N, Chitnis T, Salama AD et al. Regulatory functions of CD8+ CD28- T cells in an autoimmune disease model. J Clin Invest 2003; 112: 103748.
  • 43
    Xiao BG, Wu XC, Yang JS, Xu LY, Liu X, Huang YM, Bjelke B, Link H. Therapeutic potential of IFN-gamma-modified dendritic cells in acute and chronic experimental allergic encephalomyelitis. Int Immunol 2004; 16: 1322.